Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEK | Q02763 | 6/20 | 0.55 |
| ▸ | FLT1 | P17948 | 2/20 | 0.55 |
| ▸ | KDR | P35968 | 2/20 | 0.55 |
| ▸ | PIP4K2A | P48426 | 10/20 | 0.36 |
| ▸ | PIP4K2C | Q8TBX8 | 10/20 | 0.36 |
| ▸ | PIP4K2B | P78356 | 3/20 | 0.36 |
| ▸ | EGFR | P00533 | 2/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4797739 | 0.90 | TEK (0.55) | TEKFLT1KDRPIP4K2APIP4K2C | |
| SCHEMBL4802786 | 0.90 | TEK (0.55) | TEKFLT1KDRPIP4K2APIP4K2C | |
| SCHEMBL4797745 | 0.89 | TEK (0.69) | TEKFLT1KDRPIP4K2APIP4K2C | |
| SCHEMBL4797380 | 0.89 | TEK (0.55) | TEKFLT1KDRPIP4K2APIP4K2C | |
| SCHEMBL4800973 | 0.88 | TEK (0.53) | TEKFLT1KDRPIP4K2APIP4K2C | |
| SCHEMBL4477405 | 0.83 | TEK (0.55) | TEKFLT1KDRPIP4K2APIP4K2C | |
| SCHEMBL4796404 | 0.83 | TEK (0.79) | TEKFLT1KDRPIK3CA | |
| SCHEMBL4799294 | 0.81 | TEK (0.57) | TEKFLT1KDRPIP4K2CPIK3CA | |
| SCHEMBL4796957 | 0.79 | TEK (0.43) | TEKFLT1KDRPIP4K2APIP4K2C | |
| SCHEMBL4798593 | 0.75 | TEK (0.69) | TEKFLT1KDRPIP4K2APIP4K2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7427616-B2 | Condensed pyridines and pyrimidines with tie2 (TEK) activity | ASTRAZENECA AB (SE) | 2008-09-23 | — | — | US | disclosed |
| EP-1537112-B1 | CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2006-04-19 | — | — | EP | disclosed |
| US-20050256140-A1 | Condensed pyridines and pyrimidines with tie2 (tek) activity | ASTRAZENECA AB (SE) | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256140-A1 | Condensed pyridines and pyrimidines with tie2 (tek) activity | TIE1, TEK, KDR | TEK 2/4885FLT1 6/4885KDR 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.